- Home
- RIGL vs CPZ Comparison
RIGL vs CPZ Comparison
Compare RIGL & CPZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- CPZ
- Stock Information
- Founded
- RIGL 1996
- CPZ 2019
- Country
- RIGL United States
- CPZ United States
- Employees
- RIGL N/A
- CPZ N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- CPZ Trusts Except Educational Religious and Charitable
- Sector
- RIGL Health Care
- CPZ Finance
- Exchange
- RIGL Nasdaq
- CPZ Nasdaq
- Market Cap
- RIGL 298.0M
- CPZ 300.6M
- IPO Year
- RIGL 2000
- CPZ N/A
- Fundamental
- Price
- RIGL $17.28
- CPZ $15.25
- Analyst Decision
- RIGL Buy
- CPZ
- Analyst Count
- RIGL 5
- CPZ 0
- Target Price
- RIGL $36.80
- CPZ N/A
- AVG Volume (30 Days)
- RIGL 222.1K
- CPZ 63.0K
- Earning Date
- RIGL 05-06-2025
- CPZ 01-01-0001
- Dividend Yield
- RIGL N/A
- CPZ 11.07%
- EPS Growth
- RIGL N/A
- CPZ N/A
- EPS
- RIGL 0.99
- CPZ N/A
- Revenue
- RIGL $179,278,000.00
- CPZ N/A
- Revenue This Year
- RIGL $12.53
- CPZ N/A
- Revenue Next Year
- RIGL $15.68
- CPZ N/A
- P/E Ratio
- RIGL $17.36
- CPZ N/A
- Revenue Growth
- RIGL 54.71
- CPZ N/A
- 52 Week Low
- RIGL $7.48
- CPZ $13.17
- 52 Week High
- RIGL $29.82
- CPZ $16.11
- Technical
- Relative Strength Index (RSI)
- RIGL 44.84
- CPZ 50.81
- Support Level
- RIGL $16.05
- CPZ $14.77
- Resistance Level
- RIGL $17.52
- CPZ $15.20
- Average True Range (ATR)
- RIGL 1.26
- CPZ 0.43
- MACD
- RIGL 0.10
- CPZ 0.01
- Stochastic Oscillator
- RIGL 63.57
- CPZ 69.55
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About CPZ Calamos Long/Short Equity & Dynamic Income Trust
Calamos L/S Equity & Dynamic Inc Trust is a trust company which seeks to provide current income and risk-managed capital appreciation. The company invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary and others.